866-997-4948(US-Canada Toll Free)

Colorectal Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Nov 2010

Category :

Cancer

No. of Pages : 158 Pages


GlobalData, the industry analysis specialist, has released its new report, Colorectal Cancer Italy Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the Italian colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the Italian colorectal cancer therapeutics market. It analyses the treatment usage patterns in the Italian colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the Italian colorectal cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized Italian colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the Italian Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
  • Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in Italy.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the Italian colorectal cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the Italian colorectal cancer therapeutics market till 2020.
  • Quantifying patient population in Italy to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the Italian colorectal cancer therapeutics market from 2001 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the Italian Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7

2 Disease Overview 9
2.1 Overview 9
2.2 Epidemiology 11
2.3 Etiology 11
2.4 Symptoms 11
2.4.1 Colon Cancer 12
2.4.2 Rectal Cancer 12
2.5 Diagnosis 13
2.5.1 FOBT 13
2.5.2 Endoscopy 13
2.5.3 Optical Colonoscopy 13
2.5.4 Virtual Colonoscopy 14
2.5.5 Double Contrast Barium Enema (DCBE) 14
2.6 Pathology 14
2.6.1 Grading 14
2.7 Treatment 15
2.7.1 Colon Cancer Treatment by Stage 16
2.7.2 Rectal Cancer Treatment by Stage 18
2.7.3 Chemotherapy Options 20
2.8 Treatment Guidelines 23

3 Market Characterization 25
3.1 Italy 25
3.1.1 Market Size 25
3.1.2 Drivers and Barriers 30
3.1.3 Impact on the Market 32
3.1.4 Forecasts 33
3.1.5 Drug Sales 39
3.1.6 Pricing and Reimbursements 41
3.2 Key Takeaway 42

4 Competitor Assessment 43
4.1 Strategic Competitor Assessment 43
4.1.1 Overview 43
4.1.2 Benchmarking 43
4.1.3 Current Competitor Assessment 46
4.2 Launch Analysis and Sales Forecasts 46
4.2.1 Market Share Analysis of Drugs 46
4.3 Product Profiles 48
4.3.1 Avastin (bevacizumab) 49
4.3.2 Erbitux (cetuximab) 52
4.3.3 Xeloda (capecitabine) 56
4.3.4 Vectibix (panitumumab) 61
4.3.5 Eloxatin (oxaliplatin) 66
4.3.6 Camptosar (irinotecan) 70
4.3.7 Fluorouracil (5-FU) 72
4.3.8 Leucovorin (folinic acid) 73
4.4 Key Takeaway 74

5 Pipeline Assessment 75
5.1 Overview 75
5.2 Pipeline Analysis by Phase of Development 76
5.3 Pipeline by Mechanism of Action 77
5.4 Strategic Pipeline Assessment 78
5.4.1 Technology Trends Analytical Framework 78
5.5 Trends in Colorectal Cancer Pipeline 79
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer 79
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline 79
5.5.3 Failure of key Molecules in Phase II and Phase III Development 79
5.6 Partners in Development 80
5.6.1 Licensing Agreements by Phase of Development 80
5.6.2 Licensing Agreements by Geography 82
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology 82
5.7 Most Promising Drugs Profiles 84
5.7.1 Aflibercept 84
5.7.2 Brivanib 86
5.7.3 OncoVAX 88
5.7.4 TroVax 90
5.7.5 KRX-0401 (Perifosine) 92
5.8 Colorectal Cancer Pipeline Preclinical Phase 94
5.9 Colorectal Cancer Pipeline Phase I 94
5.10 Colorectal Cancer Pipeline Phase II 96
5.11 Colorectal Cancer Pipeline Phase III 103
5.12 Key Takeaway 105

6 Unmet Need and Target Product Profile 106
6.1 Unmet Need 108
6.2 Opportunity for Target Product 109
6.3 Target Product Profile 110
6.3.1 Ideal Characteristics 110
6.3.2 Target Product Description 110
6.4 Key Takeaway 111

7 Strategic Assessment 112
7.1 Key Events Impacting the Future Market 112
7.2 Market Impact Analysis 112
7.3 Future Market Scenario 113
7.4 Company Analysis 114
7.4.1 Market Leadership 114
7.4.2 Future Players in the Market 115
7.5 Key Takeaway 115

8 Company Profiles 116
8.1 F. Hoffmann La Roche 116
8.1.1 Business Description 116
8.1.2 Financial Overview 116
8.1.3 SWOT Analysis 117
8.2 Bristol-Myers Squibb 118
8.2.1 Business Description 118
8.2.2 Financial Overview 119
8.2.3 SWOT Analysis 119
8.3 Sanofi-Aventis 120
8.3.1 Business Description 120
8.3.2 Financial Overview 120
8.3.3 SWOT Analysis 120
8.4 Debiopharm Group 121
8.4.1 Business Description 121
8.5 Merck KGaA 122
8.5.1 Business Description 122
8.5.2 Financial Overview 122
8.5.3 SWOT Analysis 122
8.6 Regeneron 123
8.6.1 Business Description 123
8.6.2 Financial Overview 124
8.6.3 SWOT Analysis 124
8.7 Vaccinogen BD 126
8.7.1 Overview 126
8.7.2 SWOT Analysis 126
8.8 Oxford BioMedica 127
8.8.1 Business Description 127
8.8.2 Financial Overview 128
8.8.3 SWOT Analysis 128
8.9 Auron Healthcare GmbH 129
8.9.1 Company Overview 129
8.10 AEterna Zentaris 129
8.10.1 Business Description 129
8.10.2 Financial Overview 130
8.10.3 SWOT Analysis 130
8.11 Keryx 133
8.11.1 Business Description 133
8.11.2 Financial Overview 133
8.11.3 SWOT Anlaysis 133
8.12 Abbott Laboratories 136
8.12.1 Business Description 136
8.12.2 Financial Performance 136
8.12.3 SWOT Analysis 136
8.13 Pfizer 138
8.13.1 Business Description 138
8.13.2 Financial Overview 139
8.13.3 SWOT Analysis 139
8.14 Light Sciences Oncology, Inc 140
8.14.1 Business Description 140
8.14.2 Financial Overview 140
8.14.3 SWOT Analysis 141

9 Deals Analysis 143
9.1 Key Highlights 143
9.2 Key Deals Analysis 144
9.2.1 Eli Lilly Acquires ImClone 144
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 144
9.2.3 Takeda Acquires IDM Pharma 144
9.2.4 Alchemia Acquires Meditech 144
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron 144
9.2.6 BBM Holdings to Acquire YM Biosciences 144
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis 144
9.2.8 Peptech Acquires cancer Antibodies from Scancell 145
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs 145
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc 145
9.3 Deals Analysis by Geography 146
9.4 Deals Analysis by Deal Size 147

10 Expert Opinion 148
10.1 Italy 148

11 Appendix 150
11.1 Market Definitions 150
11.2 Abbreviations 150
11.3 Research Methodology 152
11.3.1 Coverage 152
11.3.2 Secondary Research 152
11.3.3 Forecasting 153
11.3.4 Primary Research 156
11.3.5 Expert Panel validation 156
11.3.6 Contact Us 156
11.3.7 Disclaimer 156
11.3.8 Sources 157

List of Table


Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010 10
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010 15
Table 3: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 20012009 25
Table 4: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20012009 26
Table 5: Colorectal Cancer Therapeutics Market, Italy, Patient Volume (000), 20012009 27
Table 6: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20012009 28
Table 7: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 20092020 33
Table 8: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20092020 34
Table 9: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 20092020 35
Table 10: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20092020 36
Table 11: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2010 40
Table 12: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011-2020 41
Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010 45
Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010 48
Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010 50
Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010 53
Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010 58
Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010 62
Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010 63
Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 67
Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010 67
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010 83
Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010 94
Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010 94
Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010 96
Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010 103
Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010 107
Table 28: Colorectal Cancer Therapeutics Market, Italy, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010 110
Table 29: Colorectal Cancer Therapeutics Market, Italy, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010 110

List of Chart


Figure 1: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010 23
Figure 2: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010 24
Figure 3: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 20012009 25
Figure 4: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20012009 26
Figure 5: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 20012009 27
Figure 6: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20012009 28
Figure 7: Colorectal Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 30
Figure 8: Colorectal Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2010 32
Figure 9: Colorectal Cancer Therapeutics Market, Italy, Sales Value ($bn), 20092020 33
Figure 10: Colorectal Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 20092020 34
Figure 11: Colorectal Cancer Therapeutics Market, Italy, Patient Volume, 20092020 35
Figure 12: Colorectal Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 20092020 36
Figure 13: Colorectal Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 20092020 38
Figure 14: Colorectal Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2020 39
Figure 15: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010 44
Figure 16: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010 46
Figure 17: Colorectal Cancer Therapeutics Market, Italy, Sales Forecast Split by Therapies, 2001-2020 47
Figure 18: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 20042010 51
Figure 19: Colorectal Cancer Therapeutics Market, Italy, Avastin, Sales Forecast ($m), 2004-2020 52
Figure 20: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 20042010 55
Figure 21: Colorectal Cancer Therapeutics Market, Italy, Erbitux, Sales Forecast ($m), 2004-2020 56
Figure 22: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010 57
Figure 23: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010 60
Figure 24: Colorectal Cancer Therapeutics Market, Italy, Sales Forecast ($m), 2001-2020 61
Figure 25: Colorectal Cancer Therapeutics Market, Global, Vectibix,Life Cyle Management Activities, 2010 64
Figure 26: Colorectal Cancer Therapeutics Market, Global, Italy, Sales Forecast ($m), 2006-2020 65
Figure 27:Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010 66
Figure 28: Colorectal Cancer Therapeutics Market, Global, Eloxatin,Life Cyle Management Activities, 2010 68
Figure 29: Colorectal Cancer Therapeutics Market, Global, Italy, Sales Forecast ($m), 2001-2020 69
Figure 30: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure 70
Figure 31: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cyle Management Activities, 2010 71
Figure 32: Colorectal Cancer Therapeutics Market, Italy, Camptosar, Sales Forecast ($m), 2001-2020 72
Figure 33: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure 72
Figure 34: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure 73
Figure 35: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010 75
Figure 36: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010 76
Figure 37: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010 77
Figure 38: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 78
Figure 39:Colorectal Cancer Therapeutics Market, Global,Technology Trends Description of Pipeline Drugs, 2010 79
Figure 40: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010 80
Figure 41:Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010 82
Figure 42:Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010 83
Figure 43: Colorectal Cancer Therapeutics Market, Italy, Aflibercept Sales Forecast ($m), 2011-2020 86
Figure 44: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010 86
Figure 45: Colorectal Cancer Therapeutics Market, Italy, Brivanib Sales Forecasts ($m), 2013-2020 88
Figure 46: Colorectal Cancer Therapeutics Market, Italy, OncoVAX Sales Forecast ($m), 2011-2020 90
Figure 47: Colorectal Cancer Therapeutics Market, Italy, TroVax Sales Forecast ($m), 2014-2020 92
Figure 48: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010 92
Figure 49: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010 106
Figure 50: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2010 109
Figure 51: Colorectal Cancer, Global, Key Events Impacting the Future Market 112
Figure 52: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010 114
Figure 53: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010 143
Figure 54: Colorectal Cancer Therapeutics Market, Global, Merger and Acqusition Deals by Geography (%), 2010 146
Figure 55: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010 147
Figure 56: Colorectal Cancer Therapeutics Market, Italy, Key Data Inputs from Key Opinion Leader Interviews, July 2010 148
Figure 57: GlobalData Market Forecasting Model 155

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *